Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;43(1):237-242.
doi: 10.3233/BD-230044.

Genomic signatures in breast cancer in a real-world setting: Experience in a Brazilian Northeastern Center

Sabas Carlos Vieira  1 , Cristiane Amaral Dos Reis  1 , Mariana Elvas Feitosa Holanda  2 , Danilo Rafael da Silva Fontinele  3 , Alessandro Igor Cavalcanti Leal  4 , Fernanda Teresa de Lima  4
Affiliations

Genomic signatures in breast cancer in a real-world setting: Experience in a Brazilian Northeastern Center

Sabas Carlos Vieira et al. Breast Dis. 2024.

Abstract

Objective: We aim to evaluate the indication and use of genomic signatures in breast cancer patients and outcomes who in patients undergoing adjuvant chemotherapy or not.

Methods: This is a retrospective study of breast cancer patients managed in a private oncology clinic in Teresina, from November 2014 to February 2021. All patients with an indication of genomic signature were included. Clinical and pathological variables, use of genomic signatures, treatment and follow-up were obtained. The nomogram to predict Oncotype DX results (University of Tennessee Medical Center) was also calculated. Clinical risk calculation was based on MINDACT, using the modified version of Adjuvant Online. The genetic signatures performed were: the Oncotype, MammaPrint and EndoPredict.

Results: Fifty (50) female patients were included in the study. The mean age of the participants was 57.1 years. Among the patients receiving a genomic signature (26-52.0%), there was a change in treatment in 8 (30.7%) cases. Chemotherapy was indicated in four patients, It was contraindicated in another four patients. Treatment changed in 30.7% of the tested patients. Chemotherapy was indicated for those who would not receive it before. It was contraindicated in patients who would previously undergo chemotherapy.

Keywords: Breast neoplasms; adjuvant; chemotherapy; gene signatures; genomics; precision medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Similar articles

See all similar articles

References

    1. Union for International Cancer Control. GLOBOCAN 2020: New Global Cancer Data | UICC. UICC | Leading the global fight against cancer, (2020, 17 de dezembro). https://www.uicc.org/news/globocan-2020-new-global-cancer-data.
    1. Ministério da Saúde. (n.d.). Estatísticas de câncer. INCA - Instituto Nacional de Câncer. https://www.inca.gov.br/numeros-de-cancer.
    1. Ministério da Saúde. (n.d.-a). Página inicial. Comiss ao Nacional de Incorporaç ao de Tecnologias no Sistema Único de Saúde. http://conitec.gov.br/.
    1. Ministério da Saúde. (n.d.-c). Página Inicial. Agência Nacional de Saúde Suplementar. https://www.ans.gov.br/.
    1. De Abreu FB, Schwartz GN, Wells WA, Tsongalis GJ, Personalized therapy for breast cancer, Clin Genet, 86: 62–67, 2014. - PubMed

LinkOut - more resources